The (ROM) for each Bethesda category The 2023 updates to the system How it compares to the TIRADS system for imaging Let me know which area you'd like to explore further.
This system is currently in its second edition (2023) and is a standard tool in cytopathology . If you'd like, I can provide:
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more Bethesda System for Reporting Thyroid Cytopathology Defin The Bethesda System for Reporting Thyroid Cytop...
It categorizes thyroid nodules into six distinct groups based on the fine needle aspiration cytology (FNAC) results, each associated with a specific risk of malignancy (RoM) and recommended management:
The sample did not have enough cells to make a diagnosis. II: Benign: High probability of being non-cancerous. The (ROM) for each Bethesda category The 2023
The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) arose from a need to standardize how doctors report thyroid biopsy results, moving away from vague, subjective language towards a uniform system that helps predict cancer risk. The Story of the Bethesda System
It ensures that a "suspicious" result means the same thing, regardless of which lab processed it. For medical advice or diagnosis, consult a professional
Indeterminate; high risk of being a follicular tumor, often requiring surgery to differentiate.